ERBB2 and breast carcinoma: TKIs combined with macromolecular targeted drugs and chemotherapy may be the main treatment method in the neoadjuvant phase for HER2-positive breast cancer patients in the future, and HER2-positive breast cancer patients with EGFR-positive may benefit more from the use of pyrotinib.